EGFR and endometrial cancer: They could reduce the viability of tumour cells by binding to the kinase domain of the human epidermal growth factor receptor 1/2 (HER1/2), and resulting in an overall reduction in global downstream signalling that was driven by overexpression of the HER family,76,77 such as lung,78 breast79 and colorectal cancer.80 We only observed that nitrogen-containing bisphosphonates could reduce 30% risk of endometrial cancer and 6% risk of breast cancer.